BioSpace News Archive

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that the Company and its subsidiaries received five prestigious Stevie® Awards in the 18th Annual American Business Awards®.

Avero Diagnostics, a physician-owned laboratory, is now providing molecular testing for COVID-19.

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that one of their two pending merger partners – Cannaworx, Inc.

Nordic Nanovector ASA announces that it will report its results for the first quarter 2020 on Tuesday, 26 May 2020.

Cart is customizable to different workflows to help caregivers attend to patients, not technology

Onxeo S.A. announced the presentation of preclinical data supporting the differentiated ability of AsiDNA™, its first-in-class DNA Damage Response inhibitor, to reverse resistance to PARP inhibitors by preventing death-tolerant cells regrowth.

Program complements ongoing efforts to build understanding of potential virucidal properties of povidone-iodine against the virus causing COVID-19

Today, Florence announces its rapidly expanding clinical research sponsor and site connectivity platform is now in use at more than 7,200 research sites and by 18,000 research professionals across 27 countries – making it the largest established site and sponsor connectivity platform in research.

The National Organization for Rare Disorders has announced new awards through its Rare Disease Research Grant Program, which provides funding to qualified researchers for translational or clinical studies related to the development of new diagnostics or treatments for rare disease.

Prellis Biologics, Inc. announced that it has generated 300 human IgG antibodies that bind to either the S1 or S2 spike protein of the SARS-CoV2-Wuhan strain of the novel coronavirus.